soluble c5b-9 smac (SMAC Corp)
Structured Review

Soluble C5b 9 Smac, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/soluble+c5b-9+smac/soluble+membrane+attack+complex/pmc09036209-8-0-2
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy"
Article Title: Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy
Journal: Hematology Reports
doi: 10.3390/hematolrep14020018
Figure Legend Snippet: TMA functional panel results. Complement biomarker profiling revealed a low FH level, an elevated Bb factor level, and the C3 level, C4 level, FB level, soluble C5b-9, and FI level were all within normal limits.
Techniques Used: Functional Assay, Biomarker Discovery, Hemolytic Assay
Related Articles
Functional Assay:Article Title: Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy Article Snippet: Article Title: Toddler With New Onset Diabetes and Atypical Hemolytic-Uremic Syndrome in the Setting of COVID-19. Article Snippet: Pre- eculizumab bloodwork revealed a low CH50 complement activity level of 3 units (normal range 60-144), with elevated Factor H, Factor I, Bb fragment level, and soluble C5b-9 (sMAC) levels (0.45 mg/L, normal <0.3). Biomarker Discovery:Article Title: Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy Article Snippet: Article Title: Toddler With New Onset Diabetes and Atypical Hemolytic-Uremic Syndrome in the Setting of COVID-19. Article Snippet: Pre- eculizumab bloodwork revealed a low CH50 complement activity level of 3 units (normal range 60-144), with elevated Factor H, Factor I, Bb fragment level, and soluble C5b-9 (sMAC) levels (0.45 mg/L, normal <0.3). Hemolytic Assay:Article Title: Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy Article Snippet: Article Title: Toddler With New Onset Diabetes and Atypical Hemolytic-Uremic Syndrome in the Setting of COVID-19. Article Snippet: Pre- eculizumab bloodwork revealed a low CH50 complement activity level of 3 units (normal range 60-144), with elevated Factor H, Factor I, Bb fragment level, and soluble C5b-9 (sMAC) levels (0.45 mg/L, normal <0.3). |